AVII Insider Trading Activity and SEC Form 4 Filings
AVII insider trading summary
No open-market insider purchases or sales of Avi Biopharma Inc (AVII) have been reported on SEC Form 4 in the past 12 months.
Latest AVII insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Mar 14, 2012 | Ben Gil Price | Director | Buy | $39K (30,000 @ $1.29) |
| Dec 15, 2011 | Nishan Garabedian Christopher | President and CEO | Buy | $174K (300,000 @ $0.58) |
| Sep 13, 2011 | Anthony R Chase | Director | Buy | $24K (20,000 @ $1.20) |
| Apr 6, 2011 | Nishan Garabedian Christopher | President and CEO | Buy | $195K (130,000 @ $1.50) |
| Apr 6, 2011 | M Kathleen Behrens | Director | Buy | $150K (100,000 @ $1.50) |
| Apr 6, 2011 | Ben Gil Price | Director | Buy | $30K (20,000 @ $1.50) |
| Aug 27, 2010 | J David Boyle II | CEO | Buy | $11K (5,000 @ $2.13) |
| Aug 13, 2010 | Ben Gil Price | Director | Buy | $8K (4,000 @ $1.93) |
| Jul 30, 2010 | Leslie Hudson | Former CEO | Sell | $36K (18,486 @ $1.94) |
| Jul 30, 2010 | Leslie Hudson | Former CEO | Sell | $97K (50,000 @ $1.93) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.